Biocentury: Singapore’s next challenge: turning momentum into sustainable growth

Published on : 14th February 2024

Read about the key role of 65LAB in Singapore’s burgeoning ecosystem, as it seeks to advance academic projects through the steps towards company formation.

Singapore venture creation group 65LAB funds novel biologics project from National University of Singapore targeting lung diseases

65LAB, a unique partnership of global investors ClavystBio, Leaps by Bayer, Lightstone Ventures, Polaris Partners and the Polaris Innovation Fund alongside Evotec, has funded

65LAB awards US$1.5 million to Duke-NUS platform to advance antifibrotic drug discovery

Recipient Professor Enrico Petretto from Duke-NUS is spearheading groundbreaking research to develop new drugs for lung disease and uncover new therapeutic targets for kidney

65LAB and Duke-NUS award US$1.85 million to combat chronic inflammation

Recipient Associate Professor Lena Ho spearheads groundbreaking research to develop first-in-class therapeutics to target inflammatory diseases Collaboration between 65LAB and Duke-NUS aims to advance